Xenon Pharmaceuticals (XENE) –
-
Form 8-K Xenon Pharmaceuticals For: Apr 15
-
Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting
-
Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
-
Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
-
Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
-
Form 4 Xenon Pharmaceuticals For: Mar 11 Filed by: Von Seggern Christopher
-
Form 4 Xenon Pharmaceuticals For: Mar 11 Filed by: AULIN SHERRY
-
Form 4 Xenon Pharmaceuticals For: Mar 11 Filed by: KENNEY CHRISTOPHER JOHN
-
Form 4 Xenon Pharmaceuticals For: Mar 11 Filed by: EMPFIELD JAMES R.
-
Form 4 Xenon Pharmaceuticals For: Mar 11 Filed by: ROBIN SHERRINGTON
-
Form 4 Xenon Pharmaceuticals For: Mar 11 Filed by: DiFabio Andrea
-
Form 4 Xenon Pharmaceuticals For: Mar 11 Filed by: MORTIMER IAN
-
Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days
-
Form 4 Xenon Pharmaceuticals For: Mar 08 Filed by: GAROFALO ELIZABETH A.
-
Form 144 Xenon Pharmaceuticals Filed by: GAROFALO ELIZABETH A.
-
Form 4 Xenon Pharmaceuticals For: Mar 07 Filed by: ROBIN SHERRINGTON
-
Form 4 Xenon Pharmaceuticals For: Mar 07 Filed by: GANNON STEVEN
-
Form 8-K Xenon Pharmaceuticals For: Mar 08
-
Form 144 Xenon Pharmaceuticals Filed by: ROBIN SHERRINGTON
-
Form 144 Xenon Pharmaceuticals Filed by: GANNON STEVEN
-
Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024
-
Xenon Pharmaceuticals (XENE) PT Raised to $62 at Needham
-
Xenon Pharmaceuticals (XENE) PT Raised to $51 at Wedbush
-
Xenon Pharmaceuticals (XENE) PT Lowered to $55 at RBC Capital
-
Xenon Pharmaceuticals (XENE) PT Raised to $55 at Wells Fargo
-
Form 10-K Xenon Pharmaceuticals For: Dec 31
-
Form 8-K Xenon Pharmaceuticals For: Feb 29
-
Xenon Pharmaceuticals (XENE) Tops Q4 EPS by 12c
-
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
-
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
-
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
-
Form SC 13G/A Xenon Pharmaceuticals Filed by: Avoro Capital Advisors LLC
-
Form SC 13G/A Xenon Pharmaceuticals Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC
-
Form SC 13G/A Xenon Pharmaceuticals Filed by: FMR LLC
-
Form SC 13G Xenon Pharmaceuticals Filed by: WELLINGTON MANAGEMENT GROUP LLP
-
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2024
-
Citi Starts Xenon Pharmaceuticals (XENE) at Buy, 'Best-In-Class Epilepsy Asset XEN1101 Offers Additional Upside in MDD'
-
Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
-
Form 4 Xenon Pharmaceuticals For: Dec 29 Filed by: ROBIN SHERRINGTON
-
Form 4 Xenon Pharmaceuticals For: Dec 19 Filed by: AZAB MOHAMMAD
-
Xenon Pharmaceuticals (XENE) PT Raised to $62 at Stifel
-
Form 4/A Xenon Pharmaceuticals For: Dec 13 Filed by: PATOU GARY
-
Form 4 Xenon Pharmaceuticals For: Dec 13 Filed by: PATOU GARY
-
Form 144 Xenon Pharmaceuticals Filed by: PATOU GARY
-
Form 144 Xenon Pharmaceuticals Filed by: PATOU GARY
-
Baird Starts Xenon Pharmaceuticals (XENE) at Outperform
-
Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
-
Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023)
-
Form 424B5 Xenon Pharmaceuticals
-
Form 8-K Xenon Pharmaceuticals For: Nov 29
Back to XENE Stock Lookup
